Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 11/20 | 0.41 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10938001 | 0.84 | CXCR4 (0.40) | CXCR4CXCL12HRH4HRH3KDM4E | |
| SCHEMBL10938415 | 0.84 | CXCR4 (0.48) | CXCR4CXCL12HRH4HRH3RAD52 | |
| SCHEMBL9417530 | 0.84 | CXCR4 (0.48) | CXCR4CXCL12HRH4HRH3RAD52 | |
| SCHEMBL10937094 | 0.84 | CXCR4 (0.48) | CXCR4CXCL12HRH4HRH3RAD52 | |
| SCHEMBL27221 | 0.84 | CXCR4 (0.48) | CXCR4CXCL12HRH4HRH3RAD52 | |
| Ammonia Solution, Strong SCHEMBL9000034 | 0.82 | CXCR4 (0.47) | CXCR4CXCL12HRH4HRH3RAD52 | |
| Hydrochloric Acid SCHEMBL11558213 | 0.82 | CXCR4 (0.47) | CXCR4CXCL12HRH4HRH3RAD52 | |
| SCHEMBL4243544 | 0.82 | CXCR4 (0.47) | CXCR4CXCL12HRH4HRH3RAD52 | |
| Hydrochloric Acid SCHEMBL9714223 | 0.82 | CXCR4 (0.47) | CXCR4CXCL12HRH4HRH3RAD52 | |
| SCHEMBL4740693 | 0.82 | CXCR4 (0.47) | CXCR4CXCL12HRH4HRH3RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820726-B2 | Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-11820726-B2 | Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20210002206-A1 | MOTUPORAMINE DERIVATIVES AS ANTIMICROBIAL AGENTS AND ANTIBIOTIC ENHANCERS AGAINST RESISTANT GRAM-NEGATIVE BACTERIA | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-01-07 | — | — | US | disclosed |
| US-10710957-B2 | Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2020-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820726-B2 | Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria | MGAM, PGLS, NISCH | CXCR4 4565/4885CXCL12 3987/4885HRH4 1569/4885 |
| US-20210002206-A1 | MOTUPORAMINE DERIVATIVES AS ANTIMICROBIAL AGENTS AND ANTIBIOTIC ENHANCERS AGAINST RESISTANT GRAM-NEGATIVE BACTERIA | MGAM, PGLS, NISCH | CXCR4 4565/4885CXCL12 3987/4885HRH4 1569/4885 |
| US-10710957-B2 | Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria | MGAM, PGLS, NISCH | CXCR4 4565/4885CXCL12 3987/4885HRH4 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.